Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3701 - Economic evaluation of eribulin in the treatment of triple negative breast cancer in the United Kingdom

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Bioethical Principles and GCP

Tumour Site

Breast Cancer

Presenters

Jaro Wex

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

J. Wex1, C. Bodnar2, C. Simon3, F. Fernandes4, N. Tanova1

Author affiliations

  • 1 Hema, Amaris, NW1 8NP - London/GB
  • 2 Global Value And Access, Eisai Europe, AL10 9SN - Hatfield/GB
  • 3 Market Access, Eisai, AL10 9SN - Hatfield/GB
  • 4 Health Economics, Eisai, AL10 9SN - Hatfield/GB
More

Resources

Abstract 3701

Background

Eribulin is indicated in the European Union for patients with locally advanced or metastatic breast cancer after ≥1 prior chemotherapy for advanced disease, including an anthracycline and a taxane. The license is based on clinical trials which included patients with triple negative breast cancer (TNBC). We sought to evaluate clinical and cost-effectiveness of eribulin in this population using decision analytic modelling.

Methods

Data on OS, PFS and TTD from TNBC patients from two randomized open label studies of eribulin, 305 (NCT00388726) and 301 (NCT00337103), were pooled (N = 352). The comparators were TPC (any single-agent chemotherapy, hormonal or biological treatment; radiotherapy; or symptomatic treatment alone) (305) and capecitabine (301). A partitioned survival model developed for the National Institute for Health and Clinical Excellence submission based on pooled Kaplan-Meier data, accounting for tumour objective response and adverse events with health-state specific utilities mapped from QLQC30 data from study 301 was used. Lifetime horizon with discount rate of 3.5% for costs and quality-adjusted life years (QALYs) was applied. Threshold analysis was based on 2017 UK costs and reimbursement decision criteria.

Results

Use of eribulin versus the pooled comparator of capecitabine or TPC was associated with greater mean overall survival (16.00 vs 12.38 months) and progression-free survival (4.4 vs 3.6 months) with 0.3 life years (LYs) gained and 0.2 incremental QALYs. 77% of LYs and 75% of QALYs were gained in progressive disease. Using UK end of life criteria and considering the patient access scheme price, eribulin falls well within the cost-effectiveness threshold of £50,000/QALY and would be considered cost-effective in the UK setting. The results were sensitive to price of eribulin, utility in the progressive disease state, discount rates and drug administration costs.

Conclusions

Eribulin is cost-effective in the treatment of patients with TNBC after ≥1 prior chemotherapy for advanced disease, including an anthracycline and a taxane in the UK.

Clinical trial identification

Legal entity responsible for the study

Amaris.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

J. Wex, N. Tanova: Research funding to the institution: Eisai. C. Bodnar, C. Simon, F. Fernandes: Employee: Eisai.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.